Human Genome Sciences, Inc. (HGSI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steven Rachbach who wrote (233)	10/12/1998 12:32:00 PM
From: David Bogdanoff	Read Replies (1) of 1127

S; Thank you for sharing your information with us. Althought your friend's assessment, if accurate, would be somewhat disappointing (the oncology market is huge), it's important to understand the limitations of an individual doctor in assessing possible uses and likely target populations of a drug. Its much more of an art than a science and a lot depends on the committment and marketing skill of the company behind the drug as the technical merits of the prospective drug. For example, a new breast cancer drug from Genentech had a long battle to make it to market and almost didn't make it. I personally saw a drug almost not marketed in the US by a major international pharmaceutical company, only to be pushed onto the market by a persistent MD. In a few years, it was was the companies biggest seller in the US. Drug development is full of such instances; the evaluation of a single doctor has some meaning only if he/she is an expert in the niche in question (ordinary practicing oncologists don't qualify) who also has specific knowledge about the business issues involved. Such people are rare and imo explains why drug development is so difficult to predict. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next